RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	JP¥76.00	-5.00%	621,900
26-10-01	JP¥80.00	0.00%	274,800
26-09-30	JP¥80.00	+2.56%	595,100
26-09-29	JP¥78.00	+1.30%	506,500
26-09-28	JP¥77.00	+1.32%	209,100

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange 02:30:00 2026-10-02 EDT			5-day change	1st Jan Change
76.00 ^JPY	-5.00%		0.00%	-2.56%

08-24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
08-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI

Market Cap	4.3B 27.25M 24.21M 22.6M 20.6M 38.84M 2.62B 39.21M 273M 106M 1.34B 102M 100M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	1.47B 9.32M 8.28M 7.73M 7.05M 13.29M 896M 13.42M 93.58M 36.26M 458M 35.01M 34.25M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	96.61%	Yield 2025 *	-	Yield 2026	-

08-24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
08-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
08-13	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
07-01	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
05-14	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
03-10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
03-10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
02-12	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-14	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
01-14	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI

25-10-07	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
24-11-05	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
24-08-03	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
23-12-05	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
22-07-29	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news: Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

25-10-08	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
24-11-06	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20-02-20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19-06-19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	-5.00%
Current month	-5.00%
1 month	-8.43%
3 months	+15.15%
6 months	-15.56%
Current year	-2.56%

1 week	74	80
1 month	74	88
Current year	57	120
1 year	57	120
3 years	57	141
5 years	57	944
10 years	57	1,109

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	2012-03-31
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	39	2023-09-30

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	2005-09-30
Toshiaki Nishihata BRD	Director/Board Member	77	2016-05-31
Takeo Adachi BRD	Director/Board Member	39	2024-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	-5.00%	0.00%	-20.83%	-40.16%	27.25M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.70%	-0.53%	+45.29%	+111.67%	39.06B
Weighted average by Cap.	+0.12%	-0.84%	+56.95%	+138.25%

	2025	2026
Net sales	2M 12.68K 11.27K 10.52K 9.58K 18.08K 1.22M 18.24K 127K 49.31K 623K 47.61K 46.58K	3M 19.02K 16.9K 15.77K 14.38K 27.11K 1.83M 27.37K 191K 73.97K 935K 71.41K 69.86K
Net income	-1.02B -6.45M -5.73M -5.35M -4.88M -9.2M -620M -9.29M -64.77M -25.1M -317M -24.23M -23.71M	-1.14B -7.26M -6.45M -6.02M -5.49M -10.35M -698M -10.45M -72.85M -28.23M -357M -27.26M -26.66M
Net Debt	-3.04B -19.26M -17.11M -15.97M -14.55M -27.45M -1.85B -27.7M -193M -74.88M -946M -72.29M -70.73M	-2.83B -17.92M -15.93M -14.86M -13.55M -25.55M -1.72B -25.79M -180M -69.7M -881M -67.3M -65.83M